NCT05911295 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05911295
Title	Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	Seagen, a wholly owned subsidiary of Pfizer
Indications	ureter transitional cell carcinoma bladder urothelial carcinoma renal pelvis transitional cell carcinoma urethra transitional cell carcinoma
Therapies	Disitamab vedotin + Pembrolizumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine
Age Groups:	adult \| senior
Covered Countries	USA \| SWE \| NOR \| NLD \| ITA \| ISR \| IRL \| HUN \| GRC \| GBR \| FRA \| ESP \| CZE \| CAN \| BRA \| BEL \| AUS \| ARG

No variant requirements are available.